Multiple studies have shown that sulindac is able to increase β-catenin degradation and decrease its nuclear translocation in breast, lung and colon cancer cells in vitro, leading to reduced expression of the β-catenin/TCF target genes [50,51,52]. Here, HNF4A is linked to malignant colon neoplasm.